Effect of pravastatin on the development of diabetes and adiponectin production.

[1]  K. Sakamoto,et al.  The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. , 2006, Clinical therapeutics.

[2]  T. Noda,et al.  Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and -independent Pathways* , 2006, Journal of Biological Chemistry.

[3]  I. G. Fantus,et al.  Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. , 2006, Atherosclerosis.

[4]  J. Hayashi,et al.  Pravastatin improves insulin resistance in dyslipidemic patients. , 2005, Journal of atherosclerosis and thrombosis.

[5]  C. Peterson,et al.  Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. , 2005, Diabetes.

[6]  S. Khalifé,et al.  Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. , 2005, Metabolism: clinical and experimental.

[7]  R. Kawamori,et al.  Acute onset and worsening of diabetes concurrent with administration of statins. , 2005, Endocrine journal.

[8]  M. Quon,et al.  Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. , 2005, Journal of the American College of Cardiology.

[9]  H. Shimano,et al.  Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. , 2005, Journal of atherosclerosis and thrombosis.

[10]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[11]  M. Quon,et al.  Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive Patients , 2004, Circulation.

[12]  Feyzullah Güçlü,et al.  Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  X. Qiang,et al.  The obesity pandemic: where have we been and where are we going? , 2004, Obesity research.

[14]  C. Mantzoros,et al.  Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. , 2004, Diabetes care.

[15]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[16]  M. Yılmaz,et al.  Fluvastatin improves insulin resistance in nondiabetic dyslpidemic patients , 2003, Endocrine.

[17]  M. Rossmeisl,et al.  Variation in type 2 diabetes--related traits in mouse strains susceptible to diet-induced obesity. , 2003, Diabetes.

[18]  H. Boeing,et al.  Adiponectin and protection against type 2 diabetes mellitus , 2003, The Lancet.

[19]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[20]  M. Matsuda,et al.  Role of Adiponectin in Preventing Vascular Stenosis , 2002, The Journal of Biological Chemistry.

[21]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[22]  T. Saruta,et al.  Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. , 2002, Metabolism: clinical and experimental.

[23]  R. Huupponen,et al.  Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. , 2002, JAMA.

[24]  S. Janciauskiene,et al.  Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. , 2002, Pharmacological research.

[25]  Lee-Ming Chuang,et al.  Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. , 2002, Diabetes care.

[26]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[27]  P. Scherer,et al.  The adipocyte-secreted protein Acrp30 enhances hepatic insulin action , 2001, Nature Medicine.

[28]  Y. Terauchi,et al.  The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity , 2001, Nature Medicine.

[29]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[30]  M. Barbagallo,et al.  Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. , 2000, Atherosclerosis.

[31]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[32]  P. Macfarlane,et al.  West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .

[33]  B. Tomlinson,et al.  Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. , 1996, Hypertension.

[34]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[35]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[36]  M. Ohrvall,et al.  A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. , 1995, Metabolism: clinical and experimental.

[37]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[38]  M. Farrer,et al.  Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. , 1994, Diabetes research and clinical practice.

[39]  W. Sheu,et al.  Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia. , 1994, American heart journal.

[40]  K. Alberti,et al.  Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria , 1993, Diabetologia.

[41]  T. Ishizaki,et al.  Effects of Provastatin, a 3-hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, on Glucose Tolerance in Patients With Essential Hypertension , 1993, Diabetes Care.

[42]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[43]  L. Niskanen,et al.  5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. , 1990, Circulation.

[44]  M. Halperin,et al.  Comparison of glucose and fructose transport into adipocytes of the rat. , 1982, The Biochemical journal.

[45]  M. Rodbell.  METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS. , 1964, The Journal of biological chemistry.

[46]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[47]  G. Paolisso,et al.  Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics , 2004, European Journal of Clinical Pharmacology.

[48]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.